Knowledge HQ

This study found that exercise mobilizes SARS-CoV-2 specific T-cells and antibodies. To assess T-cell function, SARS-CoV-2 virus-specific T-cells were expanded ex vivo from PBMCs using gas-permeable G-Rex® devices for 7 days.

This article reports a superior method for expanding NK and CAR-NK cells using 221-mIL-21 feeder cells. The expanded cells showed enhanced cytotoxicity and metabolic function. G-Rex® 6 multi-well plates were utilized for the culture and maintenance of the expanding NK cells.

This poster describes a modular, closed CAR-T manufacturing platform. It details expansion strategies using G-Rex® 100MCS for low doses and a two-step process with G-Rex® 500MCS for high doses, consistently achieving high cell viability and yields.

This study developed a GMP-compliant protocol for expanding CIK cells using G-Rex® gas-permeable. G-Rex®6 well plates yielded superior expansion and cytotoxicity compared to standard or G-Rex®6M, achieving 400-fold expansion with minimal manipulation.

This study demonstrates that anti-CD147 CAR-T and CAR-NK cells effectively kill hepatocellular carcinoma cells. To minimize toxicity, a logic-gated GPC3-synNotch system was developed. Transduced NK cells were maintained and expanded in G-Rex® 6 multi-well cell culture plates with IL-2.

This study uses targeted scRNA-seq and protein analysis to characterize human CD4+ T cells. It identifies CD80 and CD86 as markers of activated Tregs. Tregs were expanded in G-Rex®, confirming that activation induces B7 molecule expression, revealing new insights into Treg biology and heterogeneity.

This study reports the preclinical validation of ISIKOK-19 CD19 CAR-T cells for a Turkish clinical trial. Using G-Rex® 100M for expansion and BX-795 to enhance transduction, researchers produced effective CAR-T cells that eliminated tumors in vivo, demonstrating a robust and cost-effective manufacturing process.

This study evaluates the efficacy of intracerebroventricular (i.c.v.) delivery of piggyBac CD19 CAR T cells for CNS ALL. I.c.v. delivery eliminated CNS leukemia in mice, whereas intravenous delivery had only partial effects. The study supports direct CNS delivery as a potential therapeutic strategy.

This study evaluates allogeneic FLT3 CAR T cells with a safety off-switch for AML. Expanded in G-Rex® plates, these cells showed potent antileukemic activity. The off-switch allowed depletion of CAR T cells to mitigate myelotoxicity and enable bone marrow recovery, supporting clinical development.

This study presents a bifunctional fusion protein combining anti-PD-1 antibody with an engineered IL-21 mutein. Using G-Rex® for cell culture, the fusion protein demonstrated targeted IL-21 delivery to PD-1+ T cells, enhancing cytotoxicity and tumor control in mice while minimizing off-target effects.

This research demonstrates that oncolytic adenovirus coding for TNFa and IL-2 remodels the ovarian tumor microenvironment. TILs expanded in G-Rex® plates showed enhanced antitumor reactivity against autologous tumors treated with the virus. The strategy offers a promising combinatorial approach for ovarian cancer.

This study compares five CD123-CAR constructs to select a candidate for clinical trials in AML. Using G-Rex® plates for expansion, researchers identified a CD28.CD28z CAR with superior expression and function. This construct was selected for a phase 1 clinical study targeting relapsed/refractory AML.